<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Modafinil: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Modafinil: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Modafinil: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10157" href="/d/html/10157.html" rel="external">see "Modafinil: Drug information"</a> and <a class="drug drug_patient" data-topicid="10873" href="/d/html/10873.html" rel="external">see "Modafinil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F197665"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Provigil</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867599"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Alertec;</li>
<li>APO-Modafinil;</li>
<li>Auro-Modafinil;</li>
<li>JAMP Modafinil;</li>
<li>Mar-Modafinil;</li>
<li>TEVA-Modafinil</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1025755"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Central Nervous System Stimulant</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812535"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f845dc77-2ee9-46cc-b577-79468ef0fa3f">Attention-deficit/hyperactivity disorder; refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD); refractory:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to reports of serious dermatologic adverse effects and psychiatric events in children, modafinil should only be used if first- and second-line treatments have failed and the benefits outweigh the risks.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents ≤17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;30 kg: Oral: Initial: 100 mg once daily; increase daily dose in 100 mg increments every 3 to 14 days as needed; usual dose: 200 to 300 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17765380','lexi-content-ref-16841622','lexi-content-ref-19439364','lexi-content-ref-11211372','lexi-content-ref-14580657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17765380','lexi-content-ref-16841622','lexi-content-ref-19439364','lexi-content-ref-11211372','lexi-content-ref-14580657'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥30 kg: Oral: Initial: 100 mg once daily; increase daily dose in 100 mg increments every 3 to 14 days as needed; usual dose: 300 to 400 mg once daily; maximum reported dose: 500 mg/dose. Doses ≥400 mg/<b>day</b> have also been divided into two doses separated by 4 to 5 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17765380','lexi-content-ref-16841622','lexi-content-ref-17257460','lexi-content-ref-19439364','lexi-content-ref-11211372','lexi-content-ref-14580657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17765380','lexi-content-ref-16841622','lexi-content-ref-17257460','lexi-content-ref-19439364','lexi-content-ref-11211372','lexi-content-ref-14580657'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729778"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block dohp drugH1Div" id="F52729779"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment is suggested.</p></div>
<div class="block doa drugH1Div" id="F197669"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10157" href="/d/html/10157.html" rel="external">see "Modafinil: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="511dc07a-abfd-4bc3-8bcc-6f68c659481e">Cancer-related fatigue, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cancer-related fatigue, severe (in patients receiving active treatment) (off-label use): Oral:</b> Initial: 100 mg once daily for 3 days, followed by 200 mg once daily during active treatment; refer to protocol for further details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20564068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20564068'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b954c34b-ea9d-4ee8-9b3e-64119d18e72a">Hypersomnia, idiopathic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersomnia, idiopathic (off-label use): Oral:</b> 200 mg as a single daily dose in the morning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33631500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33631500'])">Ref</a></span>). Based on response and tolerability, may increase dose up to 200 mg twice daily (eg, morning and midday) or 400 mg as a single daily dose in the morning; however, evidence is limited for doses &gt;200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20465024','lexi-content-ref-21576035','lexi-content-ref-24587570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20465024','lexi-content-ref-21576035','lexi-content-ref-24587570'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (antidepressant augmentation) (off-label use):</b>
<b>Oral:</b> Initial: 100 mg/day for 3 to 7 days, then increase to 200 mg/day; further adjust dose based on response and tolerability up to 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21456039','lexi-content-ref-14628981','lexi-content-ref-18004129','lexi-content-ref-15669893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21456039','lexi-content-ref-14628981','lexi-content-ref-18004129','lexi-content-ref-15669893'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ffaacd1e-62aa-433b-b373-ab0cf4b6b33b">Multiple sclerosis–related fatigue</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis–related fatigue (off-label use):</b>
<b>Oral:</b> Initial: 100 mg/day; may increase daily dose based on response and tolerability in 100 mg increments at intervals ≥1 week up to 200 mg/day in 1 or 2 divided doses (morning and noon). Doses up to 400 mg/day have been evaluated; however, doses &gt;200 mg/day have not demonstrated greater efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20442351','lexi-content-ref-19367356','lexi-content-ref-11796766','lexi-content-ref-12195441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20442351','lexi-content-ref-19367356','lexi-content-ref-11796766','lexi-content-ref-12195441'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="57d8f44a-2462-40af-9dec-479d1351fc25">Narcolepsy-related or obstructive sleep apnea–related excessive daytime sleepiness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy-related or obstructive sleep apnea–related excessive daytime sleepiness:</b>
<b>Oral:</b> Initial: 200 mg as a single daily dose in the morning. <b>Note:</b> Doses up to 400 mg once daily have been well tolerated, but there is no consistent evidence that this dose confers additional benefit.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="548434a4-b93c-43ee-ad6a-ee28506fb9c9">Parkinson disease–related excessive daytime sleepiness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease–related excessive daytime sleepiness (off-label use): Oral:</b> Initial: 100 mg once daily; may increase dose after 1 week to 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12489899']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12489899'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6c709bd2-52fa-4b35-94aa-dcde8ec12f11">Shift work sleep disorder–related excessive daytime sleepiness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Shift work sleep disorder–related excessive daytime sleepiness:</b>
<b>Oral:</b> Initial: 200 mg as a single dose ~1 hour prior to start of work shift.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991017"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50988229"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate hepatic impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe hepatic impairment: Reduce dose to one-half of that recommended for patients with normal liver function.</p></div>
<div class="block arsc drugH1Div" id="F58527598"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular events, including <b>chest pain</b>, <b>hypertension</b>, <b>palpitations</b>, and <b>tachycardia</b> have been reported with modafinil. Serious cardiovascular events, including <b>cardiac arrhythmias</b> (eg, <b>ventricular premature contractions</b> and <b>torsades de pointes</b>), <b>cardiomyopathy</b>, and <b>heart failure</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.2011','lexi-content-ref-35197237','lexi-content-ref-16199853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.2011','lexi-content-ref-35197237','lexi-content-ref-16199853'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; related to the pharmacologic action; a sympathomedullary stimulating effect has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23484662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23484662'])">Ref</a></span>). Palpitations due to ventricular premature contractions may also occur as a result of sympathetic stimulation, though the exact mechanism is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35197237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35197237'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; increases in heart rate and blood pressure have been reported within 2 hours of modafinil administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15010183','lexi-content-ref-15753235']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15010183','lexi-content-ref-15753235'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with preexisting cardiovascular disease and/or structural heart disease (eg, mitral valve prolapse, left ventricular hypertrophy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31951804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31951804'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of mitral valve prolapse syndrome with CNS stimulants</p>
<p style="text-indent:-2em;margin-left:6em;">• Single doses ≥300 mg; total daily doses &gt;400 mg</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use with monoamine oxidase inhibitors (MAOIs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31951804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31951804'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate (eg, <b>angioedema</b>, <b>anaphylaxis</b>) and delayed hypersensitivity reactions have been reported with modafinil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.2011'])">Ref</a></span>). Delayed hypersensitivity reactions have also been reported with modafinil and may include <b>skin rash</b> and <b>fixed drug eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23723550','lexi-content-ref-25878389','lexi-content-ref-24448143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23723550','lexi-content-ref-25878389','lexi-content-ref-24448143'])">Ref</a></span>) as well as serious reactions, such as <b>multi-organ hypersensitivity reactions</b> and severe cutaneous adverse reactions (SCARs) (eg, <b>Stevens-Johnson syndrome </b>(SJS), <b>toxic epidermal necrolysis</b>, and <b>drug rash with eosinophilia and systemic symptoms</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.2011','lexi-content-ref-29028129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.2011','lexi-content-ref-29028129'])">Ref</a></span>). Manifestations of multi-organ hypersensitivity reactions are varied and may include fever and rash associated with organ system involvement, eosinophilic myocarditis, hepatitis, liver function test abnormalities, hematologic abnormalities, pruritus, and asthenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30756153','lexi-content-ref-18032767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30756153','lexi-content-ref-18032767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate hypersensitivity reactions</i>: Non–dose-related, immunologic, IgE-mediated. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-30275849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Delayed hypersensitivity reactions</i>: Non–dose-related, immunologic, T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-30275849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate hypersensitivity reactions</i>: Rapid; usually occurs within 1 hour of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.2014','lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.2014','lexi-content-ref-30275849'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Delayed hypersensitivity reactions</i>: Varied; SJS has been reported 16 to 21 days after initiating modafinil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.2011','lexi-content-ref-29028129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.2011','lexi-content-ref-29028129'])">Ref</a></span>). Fixed drug eruptions usually occur 6 to 10 days after first drug exposure and within 3 days of subsequent exposures; symptoms have been reported within 12 hours after a single dose of modafinil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23723550','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23723550','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New onset <b>mania</b> and exacerbation of psychotic or manic symptoms (eg, <b>aggressive behavior, delusion, hallucination, psychomotor agitation, psychosis</b>) have been reported with modafinil in pediatric and adult patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28360685','lexi-content-ref-30416836','lexi-content-ref-32713188','lexi-content-ref-20473083','lexi-content-ref-19171629','lexi-content-ref-15090936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28360685','lexi-content-ref-30416836','lexi-content-ref-32713188','lexi-content-ref-20473083','lexi-content-ref-19171629','lexi-content-ref-15090936'])">Ref</a></span>). <b>Suicidal ideation</b> has also been reported with modafinil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16791971','lexi-content-ref-EMA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16791971','lexi-content-ref-EMA.2011'])">Ref</a></span>), although further data is needed to determine causal relationship between modafinil and attempted suicide.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; modafinil-induced inhibition of GABA and dopamine reuptake may lead to psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28360685','lexi-content-ref-20473083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28360685','lexi-content-ref-20473083'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid: Psychotic symptoms have been reported within days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28360685','lexi-content-ref-30416836','lexi-content-ref-32713188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28360685','lexi-content-ref-30416836','lexi-content-ref-32713188'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of psychosis or psychiatric disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11879175','lexi-content-ref-16282863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11879175','lexi-content-ref-16282863'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sleep disruptions in shift workers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16199854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16199854'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F197639"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children: 12% [Greenhill 2006]), decreased appetite (children: 16% [Biederman 2005]), nausea (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (children: 20% [Biederman 2005]; adults: 34%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (3%)<span class="lexi-table-link-container"> (<a aria-label="Chest Pain table link" class="lexi-table-link" data-table-id="lexi-content-chest-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-chest-pain')">table 1</a>)</span><span class="table-link" style="display:none;">Chest Pain</span>, edema (1%), hypertension (3%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 2</a>)</span><span class="table-link" style="display:none;">Hypertension</span>, palpitations (2%)<span class="lexi-table-link-container"> (<a aria-label="Palpitations table link" class="lexi-table-link" data-table-id="lexi-content-palpitations" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-palpitations')">table 3</a>)</span><span class="table-link" style="display:none;">Palpitations</span>, tachycardia (2%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 4</a>)</span><span class="table-link" style="display:none;">Tachycardia</span>, vasodilation (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Chest Pain" frame="border" id="lexi-content-chest-pain" rules="all">
<caption style="text-align:center;">
<b>Modafinil: Adverse Reaction: Chest Pain</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Modafinil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Modafinil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200, 300, or 400 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">934</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">567</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Modafinil: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Modafinil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Modafinil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200, 300, or 400 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">934</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">567</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Palpitations" frame="border" id="lexi-content-palpitations" rules="all">
<caption style="text-align:center;">
<b>Modafinil: Adverse Reaction: Palpitations</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Modafinil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Modafinil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200, 300, or 400 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">934</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">567</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Modafinil: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Modafinil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Modafinil)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200, 300, or 400 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">934</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">567</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst (1%), weight loss (children 5% [Greenhill 2006])</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (4%), constipation (2%), diarrhea (6%), dysgeusia (1%), dyspepsia (5%), flatulence (1%), oral mucosa ulcer (1%), xerostomia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine abnormality (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (1%), anxiety (5%), chills (1%), confusion (1%), depression (2%), dizziness (5%), drowsiness (2%), emotional lability (1%), hypertonia (1%), insomnia (5%), nervousness (7%), paresthesia (2%), tremor (1%), vertigo (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (6%), dyskinesia (1%), hyperkinetic muscle activity (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (1%), epistaxis (1%), pharyngitis (4%), rhinitis (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Increased gamma-glutamyl transferase, increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (including ventricular premature contractions and torsades de pointes) (EMA 2011, Multu 2021; Oskoolilar 2005), cardiomyopathy (EMA 2011), heart failure (EMA 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme (EMA 2011), fixed drug eruption (Gaikwad 2012), skin rash (EMA 2011), Stevens-Johnson syndrome (Prince 2018), toxic epidermal necrolysis (EMA 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (EMA 2011), angioedema, (EMA 2011) drug reaction with eosinophilia and systemic symptoms (EMA 2011), multi-organ hypersensitivity reaction (EMA 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (Ranjan 2005), delusion, hallucination (Hsieh 2010), irritability (Ranjan 2005), mania (Mosholder 2009), psychosis (including psychomotor agitation) (Flavell 2021; Mosholder 2009), suicidal ideation (Block 2006)</p></div>
<div class="block coi drugH1Div" id="F197651"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to modafinil, armodafinil, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Patients in agitated states or with severe anxiety; pregnancy; females who may become pregnant.</p></div>
<div class="block war drugH1Div" id="F197636"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage reduction is recommended in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Limited information exists regarding the use of modafinil or other stimulants in patients with concomitant ADHD and seizure disorder. Whereas patients with ADHD are at an increased risk for seizure activity compared to the general population, a retrospective study using drug claims data showed that the use of stimulant medications was associated with a lower risk (Cortese 2013; Wiggs 2018). Manufacturers of some stimulants recommend discontinuing therapy if seizures occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep disorders: Appropriate use: The degree of sleepiness should be reassessed frequently; some patients may not return to a normal level of wakefulness. In obstructive sleep apnea, modafinil is indicated as treatment for excessive sleepiness and not for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating and during treatment with modafinil for excessive sleepiness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation (AACAP [Murphy 2013]; Pliszka 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Modafinil is not FDA-approved for use in pediatrics for any indication. Serious skin reactions and psychiatric events have been observed in pediatric patients treated with modafinil. The serious nature of these adverse effects resulted in the FDA’s Pediatric Advisory Committee unanimously recommending that a specific warning against the use of modafinil in children be added to the manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F197647"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Provigil: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Provigil: 200 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F197632"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F197653"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Modafinil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $11.19 - $26.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $16.93 - $39.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Provigil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $61.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $92.49</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867600"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alertec: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p></div>
<div class="block csi drugH1Div" id="F197695"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block admp drugH1Div" id="F52613357"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food; administer dose in the morning; for twice-daily dosing, separate doses by 4 to 5 hours; in pediatric trials, doses were administered in the morning and 4 to 5 hours later (midday) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16841622','lexi-content-ref-17257460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16841622','lexi-content-ref-17257460'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F11305814"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> In general, administer in dose in the morning.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Multiple sclerosis–related fatigue:</i> With multiple sclerosis–related fatigue, may consider dividing doses between morning and noon in patients experiencing post-noon fatigue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20442351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20442351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Shift work sleep disorder:</i> Administer dose ~1 hour prior to start of work shift.</p></div>
<div class="block sts drugH1Div" id="F11305813"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block meg drugH1Div" id="F10961086"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F020717s037s038lbl.pdf&amp;token=U8%2FAtQnsdkA76D9mKziKIjAd0%2F4QzP6HBkmv8Y0XvAbLMyZl97LdprlUs6ijf%2FSBV9XdkHj1mDJ%2FmN%2Bfl8ToFAju4Zci39qddkzLcw9hnkM%3D&amp;TOPIC_ID=13066" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53567889"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">To improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy and shift work sleep disorder (SWSD), as adjunctive therapy for obstructive sleep apnea/hypopnea syndrome (OSAHS) (FDA approved in adults); has also been used for attention-deficit/hyperactivity disorder (ADHD)</p></div>
<div class="block cyt drugH1Div" id="F197688"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (weak); <b>Induces</b> CYP3A4 (moderate)</p></div>
<div class="block dri drugH1Div" id="F197641"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abiraterone Acetate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Acalabrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May diminish the therapeutic effect of Modafinil.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and moderate CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Apremilast. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brexpiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inducers when possible. If combined, increase the daily dose of brigatinib in 30 mg increments after 7 days of treatment with the current brigatinib dose, up to maximum of twice the dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ceritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and impair its efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobicistat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dapsone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Delavirdine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Doravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dronedarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Duvelisib.  Management: Avoid if possible. If used, on day 12 of combination increase duvelisib from 25 mg twice daily to 40 mg twice daily or from 15 mg twice daily to 25 mg twice daily. Resume prior duvelisib dose 14 days after stopping moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Efavirenz. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Eliglustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elvitegravir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Encorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Enzalutamide. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Enzalutamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erdafitinib.  Management: Dose modifications of erdafitinib may be required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the hypertensive effect of CNS Stimulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Exemestane. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fruquintinib.  Management: Avoid this combination when possible. If combined, continue the same fruquintinib dose, but monitor for reduced fruquintinib efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and moderate CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gemigliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gepirone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glasdegib.  Management: Avoid use of glasdegib and moderate CYP3A4 inducers whenever possible. If combined, increase glasdegib dose from 100 mg daily to 200 mg daily or from 50 mg daily to 100 mg daily. Resume previous glasdegib dose 7 days after discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Idelalisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and moderate CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: CNS Stimulants may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Modafinil may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Moderate) may decrease isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Istradefylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixazomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Larotrectinib.  Management: Double the larotrectinib dose if used together with a moderate CYP3A4 inducer. Following discontinuation of the moderate CYP3A4 inducer, resume the previous dose of larotrectinib after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: Modafinil may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levoketoconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of LinaGLIPtin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lopinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Moderate) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lorlatinib.  Management: Avoid use of lorlatinib with moderate CYP3A4 inducers. If such a combination must be used, increase lorlatinib to 125 mg daily. Monitor for reduced lorlatinib efficacy and consider closer monitoring of AST, ALT, and bilirubin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Modafinil may diminish the diagnostic effect of Macimorelin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maribavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mefloquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mianserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mitapivat.  Management: Consider alternatives to this combination when possible. If combined, monitor hemoglobin and titrate mitapivat beyond 50 mg twice daily, if needed, but do not exceed doses of 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Netupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirmatrelvir and Ritonavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Osimertinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PAZOPanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used with moderate CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pirtobrutinib.  Management: Avoid concomitant use if possible. If combined, if the current pirtobrutinib dose is 200 mg once daily, increase to 300 mg once daily. If current pirtobrutinib dose is 50 mg or 100 mg once daily, increase the dose by 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, increase pralsetinib dose from 400 mg daily to 600 mg daily; from 300 mg daily to 500 mg daily; and from 200 mg daily to 300 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Praziquantel.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for reduced praziquantel efficacy. If possible, stop the moderate CYP3A4 inducer 2 to 4 weeks before praziquantel initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rilpivirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ripretinib.  Management: Avoid this combination if possible. If concomitant use is required, increase ripretinib to 150 mg twice daily. Decrease ripretinib to 150 mg once daily 14 days after stopping a moderate CYP3A4 inducer. Monitor patients for ripretinib response and toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Moderate) may decrease the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritlecitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritonavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Moderate) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rolapitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Samidorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: Modafinil may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sotorasib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tamoxifen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, sirolimus concentrations may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Temsirolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tivozanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tolvaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tucatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Upadacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vandetanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and moderate CYP3A4 inducers. If unavoidable, increase the voxelotor dose to 2,000 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zaleplon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zanubrutinib.  Management: Avoid this combination if possible. If coadministration of zanubrutinib and a moderate CYP3A4 inducer is required, increase the zanubrutinib dose to 320 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F197661"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food delays absorption, but does not affect bioavailability. Management: Administer without regard to meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F49308388"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to modafinil initiation; patients who may become pregnant should avoid modafinil use or use effective contraception during modafinil therapy (Ghaffari 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Modafinil induces cytochrome P450 enzymes, decreasing systemic exposure to drugs metabolized via CYP3A4/5. Efficacy of steroidal contraceptives (including depot and implantable contraceptives) may be decreased; alternate means of effective contraception should be used during modafinil therapy and for ≥1 month after modafinil is discontinued. Consult drug interactions database for more detailed information specific to use of modafinil and contraceptives.</p></div>
<div class="block pri drugH1Div" id="F197654"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome information following modafinil use in pregnancy is limited (Calvo-Ferrandiz 2018; Cesta 2020; Damkier 2020; Haervig 2014). Data collected from the Nuvigil/Provigil pregnancy registry suggest an increased risk of major fetal congenital malformations following in utero exposure to modafinil. Outcome information is based on 148 pregnancies reported to the registry between February 2010 and February 2019 (modafinil n=81; armodafinil n=65; both n=1). Data collected prospectively for 122 pregnancies (102 live births with known outcomes) indicated a 13% rate of major congenital malformations. When including data from retrospective live births (n=26), the malformation rate remained the same. No specific pattern of malformations was observed (Kaplan 2021). An increased risk of spontaneous abortion and intrauterine growth restriction has been reported with modafinil.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to modafinil is ongoing. Health care providers are encouraged to enroll patients exposed to modafinil during pregnancy in the registry (1-866-404-4106); pregnant patients may also enroll themselves.</p></div>
<div class="block mopp drugH1Div" id="F53567890"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Levels of sleepiness; blood pressure; heart rate; increased monitoring in patients with recent MI or unstable angina; development of severe skin reactions; development or exacerbation of psychiatric symptoms (eg, agitation, anxiety, depression).</p>
<p style="text-indent:0em;margin-top:2em;">When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (AHA [Vetter 2008]).</p></div>
<div class="block pha drugH1Div" id="F197635"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The exact mechanism of action is unclear. Modafinil has been shown to significantly increase dopamine in the brain by blocking dopamine transporters; however, has a lower affinity for dopamine receptors compared to amphetamines (Volkow 2009). EEG studies have shown modafinil increases high-frequency alpha waves while decreasing both delta and theta wave activity, effects consistent with generalized increases in mental alertness (James 2011). Studies also have demonstrated decreased GABA-mediated neurotransmission through increased turnover of serotonin and enhanced activity of 5-HT<sub>2</sub> receptors and that an intact central alpha-adrenergic system is required for modafinil's activity (Kumar 2008; Schwartz 2008).</p></div>
<div class="block phk drugH1Div" id="F197650"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Modafinil is a racemic compound (10% S-isomer and 90% R-isomer at steady state) whose enantiomers have different pharmacokinetics </p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;">Distribution: V<sub>d</sub>: 0.9 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~60%, primarily to albumin </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; multiple pathways including CYP3A4 </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Effective half-life: 15 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 2 to 4 hours; may be delayed ~1 hour with food. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (80% as metabolites, &lt;10% as unchanged drug); feces (1%)</p></div>
<div class="block phksp drugH1Div" id="F51159681"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In severe, chronic renal failure (CrCl ≤20 mL/minute), exposure to modafinil acid (inactive metabolite) was increased 9-fold.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with cirrhosis of the liver, clearance is decreased ~60% and steady-state concentrations are doubled.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Oral clearance decreased ~20% in patients with a mean age of 63 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F197655"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Modiodal</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Intensit | Nopral | Vigicer | Visper</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Modafinil aristo | Modasomil</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-modafinil | Modafin | Modafinil an | Modafinil gh | Modafinil mylan | Modavigil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Provigil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Aspendos</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Stavigile</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Modasomil</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alertex | Mentix | Modavitae | Naxelan | Resotyl</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alerticine | Carim | Modafilo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aspendos | Vigil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Modafinil aurobindo | Modafinil glenmark | Modafinil Heumann | Modafinil neuraxpharm | Provigil | Vigil</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Resotyl</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alertex | Carim</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Modafinil aurobindo | Modafinil glenmark | Modiodal | Provigil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bravamax | Modasomil | Modifree</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Modafinilo aristo | Modafinilo Aurobindo | Modafinilo bluefish | Modafinilo Mylan | Modafinilo tarbis | Modiodal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Modafinil orion</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Modafinil arrow | Modafinil biogaran | Modafinil cephalon | Modafinil EG | Modafinil mylan | Modiodal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Modafinil mylan | Provigil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aspendos | Modiodal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Prosentio | Provigil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Provigil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Modafil | Modalert | Modapro | Modatec | Modfast | Modnite | Provake</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Provigil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Modiodal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Modanil | Provigil</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo-modafinil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Modafinil arrow | Modiodal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Modiodal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Provigil</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Modafinil aurobindo | Modafinil neuraxpharm | Modiodal | Provigil</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aditral | Maverany | Modiodal | Weicop | Zauroness | Zydilo</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Provigil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aspendos | Modafinil mylan | Modiodal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Modafinil Orifarm | Modiodal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Modavigil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bolixin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dowvigil | V zac</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Actimodan | Modafinil glenmark | Provigil | Vigil</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Provigil</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Modafinil Generis | Modafinil wynn | Modiodal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bolixin | Provigil</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aspendos</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-modafinil | Modiodal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Modafinil 2care4 | Modafinil bluefish | Modafinil mylan | Modafinil Orifarm | Modafinil orion | Modafinil sandoz | Modiodal | Myldamo</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Provigil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Altasomil | Vigil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aspendos | Vigil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cralium | Modiodal | Modiogen | Modivigil | Modiwake</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Provigil</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Carim | Movigil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Modafinil ipharma | Provigil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21456039">
<a name="21456039"></a>Abolfazli R, Hosseini M, Ghanizadeh A, et al. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. <i>Depress Anxiety</i>. 2011;28(4):297-302. doi:10.1002/da.20801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/21456039/pubmed" id="21456039" target="_blank">21456039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12621632">
<a name="12621632"></a>Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. <i>Mov Disord</i>. 2003;18(3):287-293. doi:10.1002/mds.10390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/12621632/pubmed" id="12621632" target="_blank">12621632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alertec.1">
<a name="Alertec.1"></a>Alertec (modafinil) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20465024">
<a name="20465024"></a>Ali M, Auger RR, Slocumb NL, Morgenthaler TI. Idiopathic hypersomnia: clinical features and response to treatment. <i>J Clin Sleep Med</i>. 2009;5(6):562-568.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/20465024/pubmed" id="20465024" target="_blank">20465024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23484662">
<a name="23484662"></a>Amar J, Lieber A, Montastruc F, Bagheri H, Pathak A, Montastruc JL. Arterial hypertension and resistance to antihypertensive treatment: a new adverse drug reaction with modafinil. <i>Therapie</i>. 2013;68(1):53-54. doi:10.2515/therapie/2013007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/23484662/pubmed" id="23484662" target="_blank">23484662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17765380">
<a name="17765380"></a>Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S. Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2008;32(1):145-149. doi:10.1016/j.pnpbp.2007.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/17765380/pubmed" id="17765380" target="_blank">17765380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30518447">
<a name="30518447"></a>Aurora S, Aurora N, Datta P, Rewers-Felkins K, Baker T, Hale TW. Evaluating transfer of modafinil into human milk during lactation: a case report. <i>J Clin Sleep Med</i>. 2018;14(12):2087-2089. doi:10.5664/jcsm.7546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/30518447/pubmed" id="30518447" target="_blank">30518447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28360685">
<a name="28360685"></a>Aytaş Ö, Dilek Yalvaç H. Modafinil-Induced Psychosis: A Case Report. <i>Noro Psikiyatr Ars</i>. 2015;52(1):99-101. doi:10.5152/npa.2015.7160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/28360685/pubmed" id="28360685" target="_blank">28360685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30756153">
<a name="30756153"></a>Bäuml M, Udi J, Klingel K, et al. Severe eosinophilic myocarditis associated with modafinil in a patient with normal peripheral eosinophil count. <i>Clin Res Cardiol</i>. 2019;108(8):963-966. doi:10.1007/s00392-019-01434-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/30756153/pubmed" id="30756153" target="_blank">30756153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16322134">
<a name="16322134"></a>Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, flexible-dose study. <i>Pediatrics</i>. 2005;116(6):e777-784. doi:10.1542/peds.2005-0617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/16322134/pubmed" id="16322134" target="_blank">16322134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16841622">
<a name="16841622"></a>Biederman J, Swanson JM, Wigal SB, et al. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. <i>J Clin Psychiatry</i>. 2006;67(5):727-735. doi:10.4088/jcp.v67n0506<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/16841622/pubmed" id="16841622" target="_blank">16841622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19416039">
<a name="19416039"></a>Blackhall L, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. <i>J Palliat Med</i>. 2009;12(5):433-439. doi:10.1089/jpm.2008.0230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/19416039/pubmed" id="19416039" target="_blank">19416039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16791971">
<a name="16791971"></a>Block J. Serious adverse events and the modafinil augmentation study. <i>CNS Spectr</i>. 2006;11(5):340; author reply 340-342. doi:10.1017/s1092852900014449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/16791971/pubmed" id="16791971" target="_blank">16791971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17257460">
<a name="17257460"></a>Boellner SW, Earl CQ, Arora S. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study. <i>Curr Med Res Opin</i>. 2006;22(12):2457-2465. doi:10.1185/030079906X148300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/17257460/pubmed" id="17257460" target="_blank">17257460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24733803">
<a name="24733803"></a>Bower JE, Bak K, Berger A, et al; American Society of Clinical Oncology. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. <i>J Clin Oncol</i>. 2014;32(17):1840-1850. doi:10.1200/JCO.2013.53.4495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/24733803/pubmed" id="24733803" target="_blank">24733803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20442351">
<a name="20442351"></a>Brown JN, Howard CA, Kemp DW. Modafinil for the treatment of multiple sclerosis-related fatigue. <i>Ann Pharmacother</i>. 2010;44(6):1098-1103. doi:10.1345/aph.1M705<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/20442351/pubmed" id="20442351" target="_blank">20442351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28568319">
<a name="28568319"></a>Calvo-Ferrandiz E, Peraita-Adrados R. Narcolepsy with cataplexy and pregnancy: a case-control study. <i>J Sleep Res</i>. 2018;27(2):268-272. doi:10.1111/jsr.12567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/28568319/pubmed" id="28568319" target="_blank">28568319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32870289">
<a name="32870289"></a>Cesta CE, Engeland A, Karlsson P, Kieler H, Reutfors J, Furu K. Incidence of malformations after early pregnancy exposure to modafinil in Sweden and Norway. <i>JAMA</i>. 2020;324(9):895-897. doi:10.1001/jama.2020.9840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/32870289/pubmed" id="32870289" target="_blank">32870289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23294014">
<a name="23294014"></a>Cortese S, Holtmann M, Banaschewski T, et al; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. <i>J Child Psychol Psychiatry</i>. 2013;54(3):227-246. doi:10.1111/jcpp.12036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/23294014/pubmed" id="23294014" target="_blank">23294014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990303">
<a name="31990303"></a>Damkier P, Broe A. First-trimester pregnancy exposure to modafinil and risk of congenital malformations. <i>JAMA</i>. 2020;323(4):374-376. doi:10.1001/jama.2019.20008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/31990303/pubmed" id="31990303" target="_blank">31990303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14628981">
<a name="14628981"></a>DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR; Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. <i>J Clin Psychiatry</i>. 2003;64(9):1057-1064. doi:10.4088/jcp.v64n0911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/14628981/pubmed" id="14628981" target="_blank">14628981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30416836">
<a name="30416836"></a>DiSciullo AA, English CD, Horn WT. Modafinil induced psychosis in a patient with bipolar 1 depression. <i>Case Rep Psychiatry</i>. 2018;2018:3732958. doi: 101155/2018/3732958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/30416836/pubmed" id="30416836" target="_blank">30416836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18004129">
<a name="18004129"></a>Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. <i>J Clin Psychopharmacol</i>. 2007;27(6):614-619. doi:10.1097/jcp.0b013e31815abefb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/18004129/pubmed" id="18004129" target="_blank">18004129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMA.2011">
<a name="EMA.2011"></a>European Medicines Agency (EMA). Assessment report for modafinil containing medicinal products. 2011;doc ref EMA/4038/2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15669893">
<a name="15669893"></a>Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. <i>J Clin Psychiatry</i>. 2005;66(1):85-93. doi:10.4088/jcp.v66n0112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/15669893/pubmed" id="15669893" target="_blank">15669893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32713188">
<a name="32713188"></a>Flavell J. Modafinil-induced psychosis in a patient with attention deficit hyperactivity disorder. <i>Australas Psychiatry</i>. 2021;29(3):366-367. doi:10.1177/1039856220936630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/32713188/pubmed" id="32713188" target="_blank">32713188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23723550">
<a name="23723550"></a>Gaikwad GV, Dhuri CV. Modafinil-induced fixed drug eruption. <i>Indian J Psychol Med</i>. 2012;34(4):383-384. doi:10.4103/0253-7176.108227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/23723550/pubmed" id="23723550" target="_blank">23723550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33074296">
<a name="33074296"></a>Ghaffari N, Robertson PA. Caution in prescribing modafinil and armodafinil to individuals who could become pregnant. <i>JAMA Intern Med</i>. 2021;181(2):277-278. doi:10.1001/jamainternmed.2020.4206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/33074296/pubmed" id="33074296" target="_blank">33074296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25878389">
<a name="25878389"></a>Ghoshal L, Sinha M. Fixed drug eruptions with modafinil. <i>Indian J Pharmacol</i>. 2015;47(2):224-226. doi:10.4103/0253-7613.153437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/25878389/pubmed" id="25878389" target="_blank">25878389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24330897">
<a name="24330897"></a>Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CHY. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. <i>J Clin Psychiatry</i>. 2013;74(11):1101-1107. doi:10.4088/JCP.13r08560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/24330897/pubmed" id="24330897" target="_blank">24330897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16601402">
<a name="16601402"></a>Greenhill LL, Biederman J, Boellner SW, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. <i>J AM Acad Child Adolesc Psychiatry</i>. 2006;45(5):503-511. doi:10.1097/01.chi.0000205709.63571.c9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/16601402/pubmed" id="16601402" target="_blank">16601402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24590619">
<a name="24590619"></a>Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. <i>Pharmacoepidemiol Drug Saf</i>. 2014;23(5):526-533. doi:10.1002/pds.3600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/24590619/pubmed" id="24590619" target="_blank">24590619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12489899">
<a name="12489899"></a>Högl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. <i>Sleep</i>. 2002;25(8):905-909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/12489899/pubmed" id="12489899" target="_blank">12489899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20473083">
<a name="20473083"></a>Hsieh CF, Lai CL, Lan SH, Liu CK, Hsu CY. Modafinil-associated vivid visual hallucination in a patient with Kleine-Levin syndrome: case report. <i>J Clin Psychopharmacol</i>. 2010;30(3):347-350. doi:10.1097/JCP.0b013e3181debcd9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/20473083/pubmed" id="20473083" target="_blank">20473083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33631500">
<a name="33631500"></a>Inoue Y, Tabata T, Tsukimori N. Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time: a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study. <i>Sleep Med.</i> 2021;80:315-321. doi:10.1016/j.sleep.2021.01.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/33631500/pubmed" id="33631500" target="_blank">33631500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21301819">
<a name="21301819"></a>James LM, Iannone R, Palcza J, et al. Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. <i>Psychopharmacology (Berl)</i>. 2011;215(4):643-653. doi:10.1007/s00213-010-2158-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/21301819/pubmed" id="21301819" target="_blank">21301819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20564068">
<a name="20564068"></a>Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. <i>Cancer.</i> 2010;116(14):3513-3520. doi:10.1002/cncr.25083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/20564068 /pubmed" id="20564068 " target="_blank">20564068 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19439364">
<a name="19439364"></a>Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. <i>Psychiatry Res</i>. 2009;168(3):234-237. doi:10.1016/j.psychres.2008.06.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/19439364/pubmed" id="19439364" target="_blank">19439364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33074297">
<a name="33074297"></a>Kaplan S, Braverman DL, Frishman I, Bartov N. Pregnancy and fetal outcomes following exposure to modafinil and armodafinil during pregnancy. <i>JAMA Intern Med</i>. 2021;181(2):275-277. doi:10.1001/jamainternmed.2020.4009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/33074297/pubmed" id="33074297" target="_blank">33074297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486148">
<a name="27486148"></a>Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. <i>Can J Psychiatry</i>. 2016;61(9):540-560. doi:10.1177/0706743716659417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/27486148/pubmed" id="27486148" target="_blank">27486148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18729534">
<a name="18729534"></a>Kumar R. Approved and investigational uses of modafinil: An evidence-based review. <i>Drugs.</i> 2008, 68(13):1803-1839. doi:10.2165/00003495-200868130-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/18729534/pubmed" id="18729534" target="_blank">18729534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19367356">
<a name="19367356"></a>Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. <i>J Neurol</i>. 2009;256(4):645-650. doi:10.1007/s00415-009-0152-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/19367356/pubmed" id="19367356" target="_blank">19367356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21576035">
<a name="21576035"></a>Lavault S, Dauvilliers Y, Drouot X, et al. Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. <i>Sleep Med</i>. 2011;12(6):550-556. doi:10.1016/j.sleep.2011.03.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/21576035/pubmed" id="21576035" target="_blank">21576035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15010183">
<a name="15010183"></a>Makris AP, Rush CR, Frederich RC, Kelly TH. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. <i>Appetite</i>. 2004;42(2):185-195. doi:10.1016/j.appet.2003.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/15010183/pubmed" id="15010183" target="_blank">15010183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16199854">
<a name="16199854"></a>Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work. <i>Am J Psychiatry</i>. 2005;162(10):1983. doi:10.1176/appi.ajp.162.10.1983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/16199854/pubmed" id="16199854" target="_blank">16199854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34743789">
<a name="34743789"></a>Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. <i>J Clin Sleep Med</i>. 2021;17(9):1881-1893. doi:10.5664/jcsm.9328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/34743789/pubmed" id="34743789" target="_blank">34743789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25196321">
<a name="25196321"></a>Mayer G, Benes H, Young P, Bitterlich M, Rodenbeck A. Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study. <i>J Sleep Res.</i> 2015;24(1):74-81. doi:10.1111/jsr.12201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/25196321/pubmed" id="25196321" target="_blank">25196321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21561959">
<a name="21561959"></a>Möller F, Poettgen J, Broemel F, Neuhaus A, Daumer M, Heesen C. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. <i>Mult Scler</i>. 2011;17(8):1002-1009. doi:10.1177/1352458511402410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/21561959/pubmed" id="21561959" target="_blank">21561959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18246980">
<a name="18246980"></a>Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. <i>Sleep</i>. 2007;30(12):1705-1711. doi:10.1093/sleep/30.12.1705<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/18246980/pubmed" id="18246980" target="_blank">18246980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19171629">
<a name="19171629"></a>Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. <i>Pediatrics</i>. 2009;123(2):611-616. doi:10.1542/peds.2008-0185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/19171629/pubmed" id="19171629" target="_blank">19171629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290467">
<a name="24290467"></a>Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359. doi:10.1016/j.jaac.2013.09.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/24290467/pubmed" id="24290467" target="_blank">24290467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35197237">
<a name="35197237"></a>Mutlu D, Kültürsay B, Karagöz A. Modafinil-induced ventricular arrhythmia: A case report. <i>Turk Kardiyol Dern Ars</i>. 2022;50(1):79-82. doi:10.5543/tkda.2022.21084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/35197237/pubmed" id="35197237" target="_blank">35197237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11879175">
<a name="11879175"></a>Narendran R, Young CM, Valenti AM, Nickolova MK, Pristach CA. Is psychosis exacerbated by modafinil? <i>Arch Gen Psychiatry</i>. 2002;59(3):292-293. doi:10.1001/archpsyc.59.3.292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/11879175/pubmed" id="11879175" target="_blank">11879175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. https://www.nice.org.uk/guidance/cg183. Published September 3, 2014. Accessed November 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33242419">
<a name="33242419"></a>Nourbakhsh B, Revirajan N, Morris B, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. <i>Lancet Neurol</i>. 2021;20(1):38-48. doi:10.1016/S1474-4422(20)30354-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/33242419/pubmed" id="33242419" target="_blank">33242419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16291885">
<a name="16291885"></a>Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. <i>J Neurol Neurosurg Psychiatry</i>. 2005;76(12):1636-1639. doi:10.1136/jnnp.2005.065870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/16291885/pubmed" id="16291885" target="_blank">16291885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16199853">
<a name="16199853"></a>Oskooilar N. A case of premature ventricular contractions with modafinil. <i>Am J Psychiatry</i>. 2005;162(10):1983-1984. doi:10.1176/appi.ajp.162.10.1983-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/16199853/pubmed" id="16199853" target="_blank">16199853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24587570">
<a name="24587570"></a>Philip P, Chaufton C, Taillard J, et al. Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial. <i>Sleep</i>. 2014;37(3):483-487. doi:10.5665/sleep.3480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/24587570/pubmed" id="24587570" target="_blank">24587570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581453">
<a name="17581453"></a>Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7):894-921. doi:10.1097/chi.0b013e318054e724.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/17581453/pubmed" id="17581453" target="_blank">17581453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29028129">
<a name="29028129"></a>Prince V, Philippidou M, Walsh S, Creamer D. Stevens-Johnson syndrome induced by modafinil. <i>Clin Exp Dermatol</i>. 2018;43(2):191-192. doi:10.1111/ced.13282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/29028129/pubmed" id="29028129" target="_blank">29028129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Provigil.1">
<a name="Provigil.1"></a>Provigil (modafinil) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11796766">
<a name="11796766"></a>Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. <i>J Neurol Neurosurg Psychiatry</i>. 2002;72(2):179-183. doi:10.1136/jnnp.72.2.179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/11796766/pubmed" id="11796766" target="_blank">11796766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16282863">
<a name="16282863"></a>Ranjan S, Chandra PS. Modafinil-induced irritability and aggression? A report of 2 bipolar patients. <i>J Clin Psychopharmacol</i>. 2005;25(6):628-629. doi:10.1097/01.jcp.0000185346.77966.a4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/16282863/pubmed" id="16282863" target="_blank">16282863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15090936">
<a name="15090936"></a>Rosenthal MH, Bryant SL. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. <i>Clin Neuropharmacol</i>. 2004;27(1):38-43. doi:10.1097/00002826-200401000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/15090936/pubmed" id="15090936" target="_blank">15090936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11211372">
<a name="11211372"></a>Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. <i>J Am Acad Child Adolesc Psychiatry</i>. 2001;40(2):230-235. doi:10.1097/00004583-200102000-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/11211372/pubmed" id="11211372" target="_blank">11211372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14580657">
<a name="14580657"></a>Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. <i>Pediatr Neurol</i>. 2003;29(2):136-142. doi:10.1016/s0887-8994(03)00148-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/14580657/pubmed" id="14580657" target="_blank">14580657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18032767">
<a name="18032767"></a>Sabatine MS, Poh KK, Mega JL, Shepard JA, Stone JR, Frosch MP. Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension. <i>N Engl J Med</i>. 2007;357(21):2167-2178. doi:10.1056/NEJMcpc079030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/18032767/pubmed" id="18032767" target="_blank">18032767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19920895">
<a name="19920895"></a>Schwartz JR. Modafinil in the treatment of excessive sleepiness. <i>Drug Des Devel Ther. </i>2008;2:71-85. doi:10.2147/dddt.s2377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/19920895/pubmed" id="19920895" target="_blank">19920895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29175676">
<a name="29175676"></a>Shangyan H, Kuiqing L, Yumin X, Jie C, Weixiong L. Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. <i>Mult Scler Relat Disord</i>. 2018;19:85-89. doi:10.1016/j.msard.2017.10.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/29175676/pubmed" id="29175676" target="_blank">29175676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24312590">
<a name="24312590"></a>Sheng P, Hou L, Wang X, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. <i>PLoS One</i>. 2013;8(12):e81802. doi:10.1371/journal.pone.0081802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/24312590/pubmed" id="24312590" target="_blank">24312590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24448143">
<a name="24448143"></a>Sonthalia S, Arora R, Sarkar R, Dhawan A, Srivastava A. Fixed drug eruption due to modafinil. <i>Indian J Dermatol Venereol Leprol</i>. 2014;80(1):90-92. doi:10.4103/0378-6323.125497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/24448143/pubmed" id="24448143" target="_blank">24448143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31951804">
<a name="31951804"></a>Sousa A, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. <i>Subst Abus</i>. 2020;41(2):155-173. doi:10.1080/08897077.2019.1700584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/31951804/pubmed" id="31951804" target="_blank">31951804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15824337">
<a name="15824337"></a>Stankoff B, Waubant E, Confavreux C, et al; French Modafinil Study Group. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. <i>Neurology</i>. 2005;64(7):1139-1143. doi:10.1212/01.WNL.0000158272.27070.6A<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/15824337/pubmed" id="15824337" target="_blank">15824337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15753235">
<a name="15753235"></a>Taneja I, Diedrich A, Black BK, Byrne DW, Paranjape SY, Robertson D. Modafinil elicits sympathomedullary activation. <i>Hypertension</i>. 2005;45(4):612-618. doi:10.1161/01.HYP.0000158267.66763.63<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/15753235/pubmed" id="15753235" target="_blank">15753235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34031871">
<a name="34031871"></a>Trotti LM, Becker LA, Friederich Murray C, Hoque R. Medications for daytime sleepiness in individuals with idiopathic hypersomnia. <i>Cochrane Database Syst Rev</i>. 2021;5(5):CD012714. doi:10.1002/14651858.CD012714.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/34031871/pubmed" id="34031871" target="_blank">34031871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18427125">
<a name="18427125"></a>Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/18427125/pubmed" id="18427125" target="_blank">18427125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19293415">
<a name="19293415"></a>Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. <i>JAMA</i>. 2009;301(11):1148-1154. doi:10.1001/jama.2009.351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/19293415/pubmed" id="19293415" target="_blank">19293415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275849">
<a name="30275849"></a>Warrington R, Silviu-Dan F, Wong T. Drug allergy. <i>Allergy Asthma Clin Immunol</i>. 2018;14(suppl 2):60. doi:10.1186/s13223-018-0289-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/30275849/pubmed" id="30275849" target="_blank">30275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29476037">
<a name="29476037"></a>Wiggs KK, Chang Z, Quinn PD, et al. Attention-deficit/hyperactivity disorder medication and seizures. <i>Neurology</i>. 2018;90(13):e1104-e1110. doi:10.1212/WNL.0000000000005213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/29476037/pubmed" id="29476037" target="_blank">29476037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12195441">
<a name="12195441"></a>Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. <i>J Neurol</i>. 2002;249(8):983-987. doi:10.1007/s00415-002-0765-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/modafinil-pediatric-drug-information/abstract-text/12195441/pubmed" id="12195441" target="_blank">12195441</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13066 Version 462.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
